Anlotinib Plus Anti-PD-1 Antibody AK105 for Advanced Pancreatic Cancer

Chinese Academy of Medical Sciences & Peking Union Medical College

Status and phase: Enrolling; Phase 2; Phase 1

Conditions: Anlotinib; Anti-PD-1 Antibody; Advanced Pancreatic Cancer

Treatments: Drug: Anlotinib plus AK105

Study type: Interventional

Funder types: Other

Identifiers

NCT04803851

JS2791

Details and patient eligibility

About

This study was designed to explore the clinical efficacy of Anlotinib combined with Anti-PD-1 antibody AK105 in the treatment of third- and above -line advanced pancreatic cancer patients, in order to find a better therapy strategy for pancreatic cancer patients.

Enrollment: 29 estimated patients

Sex: All

Ages: 18 to 75 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• locally advanced or metastatic pancreatic cancer (PC),
• histologically or cytologically proven diagnosis of adenocarcinoma or adenosquamous carcinoma,
• failed to second-line chemotherapy for PC,
• 18-75 years of age,
• an Eastern Cooperative Oncology Group performance status score of 0 to 1,
• adequate organ functions

Exclusion criteria

• had received PD 1 /CTLA 4 antibody treatment
• had received anti-VEGFR inhibitors or antibodies

Trial design

Primary purpose: Treatment

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

29 participants in 1 patient group

Treatment group

Experimental group

Description:

Anlotinib plus AK105

Treatment:

Drug: Anlotinib plus AK105